AU2016396661B2 - Cross-linking agents and associated methods - Google Patents

Cross-linking agents and associated methods Download PDF

Info

Publication number
AU2016396661B2
AU2016396661B2 AU2016396661A AU2016396661A AU2016396661B2 AU 2016396661 B2 AU2016396661 B2 AU 2016396661B2 AU 2016396661 A AU2016396661 A AU 2016396661A AU 2016396661 A AU2016396661 A AU 2016396661A AU 2016396661 B2 AU2016396661 B2 AU 2016396661B2
Authority
AU
Australia
Prior art keywords
copper
composition
treatment
cross
cornea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016396661A
Other languages
English (en)
Other versions
AU2016396661A1 (en
Inventor
Balamurali K. Ambati
Santosh MUDDANA
Hironori UEHARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2016396661A1 publication Critical patent/AU2016396661A1/en
Application granted granted Critical
Publication of AU2016396661B2 publication Critical patent/AU2016396661B2/en
Priority to AU2023202236A priority Critical patent/AU2023202236B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016396661A 2016-03-08 2016-12-06 Cross-linking agents and associated methods Active AU2016396661B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202236A AU2023202236B2 (en) 2016-03-08 2023-04-12 Cross-linking agents and associated methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305227P 2016-03-08 2016-03-08
US62/305,227 2016-03-08
PCT/US2016/065215 WO2017155580A1 (en) 2016-03-08 2016-12-06 Cross-linking agents and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202236A Division AU2023202236B2 (en) 2016-03-08 2023-04-12 Cross-linking agents and associated methods

Publications (2)

Publication Number Publication Date
AU2016396661A1 AU2016396661A1 (en) 2018-09-27
AU2016396661B2 true AU2016396661B2 (en) 2023-01-19

Family

ID=59790799

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016396661A Active AU2016396661B2 (en) 2016-03-08 2016-12-06 Cross-linking agents and associated methods
AU2023202236A Active AU2023202236B2 (en) 2016-03-08 2023-04-12 Cross-linking agents and associated methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202236A Active AU2023202236B2 (en) 2016-03-08 2023-04-12 Cross-linking agents and associated methods

Country Status (8)

Country Link
US (3) US11065275B2 (cg-RX-API-DMAC10.html)
EP (2) EP3426262B1 (cg-RX-API-DMAC10.html)
JP (3) JP6929010B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250026890A (cg-RX-API-DMAC10.html)
AU (2) AU2016396661B2 (cg-RX-API-DMAC10.html)
CA (1) CA3016688A1 (cg-RX-API-DMAC10.html)
ES (1) ES2959242T3 (cg-RX-API-DMAC10.html)
WO (1) WO2017155580A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ES2959242T3 (es) * 2016-03-08 2024-02-22 Univ Utah Res Found Agentes de reticulación y métodos asociados
US11524032B2 (en) 2018-01-05 2022-12-13 University Of Utah Research Foundation Treatment of myopic progression
US12344598B2 (en) 2019-01-25 2025-07-01 Avedro, Inc. Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders
EP3996644A4 (en) * 2019-07-11 2023-07-26 University of Utah Research Foundation MULTI-AGENT OCULAR FORMULATIONS AND METHODS OF TREATMENT
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN114082960B (zh) * 2021-11-11 2023-01-17 江苏徐工工程机械研究院有限公司 轴套的制备方法、轴套及挖掘机
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
KR102984516B1 (ko) * 2023-08-01 2026-06-30 대구가톨릭대학교산학협력단 엑소좀 억제제를 포함하는 항암용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490389A (en) * 1976-03-11 1984-12-25 Nelson Research & Development Co. Contact lens preserving solution containing ascorbic acid or salts thereof
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
US7351715B2 (en) * 1998-09-21 2008-04-01 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
WO2016162795A1 (en) * 2015-04-09 2016-10-13 Laboratori Baldacci S.P.A. Pyrrolidone carboxylic acid (pca) for ophthalmic use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655919B2 (en) * 1990-02-22 1995-01-19 Macnaught Pty Limited Artificial tears
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5997911A (en) * 1996-08-27 1999-12-07 Brinton Veterinary Supply, Inc. Composition and method for reducing diarrhea in poultry and swine
JPH10273322A (ja) * 1997-01-30 1998-10-13 Kubota Corp 抗菌性複合チタン酸化合物およびその製造方法
WO1999045869A1 (en) * 1998-03-09 1999-09-16 Ista Pharmaceuticals, Inc. Use of corneal hardening agents in enzyme orthokeratology
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
MXPA03005380A (es) * 2000-11-16 2004-02-18 Kenneth T Zeiler Composicion antifungica para unas y metodo para su uso.
US7767652B2 (en) * 2004-07-21 2010-08-03 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
US20060165611A1 (en) * 2005-01-26 2006-07-27 National Research Laboratories, Ltd. Composition for Treating and Preventing Periodontal Disease and Method of Use
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
KR20090087917A (ko) * 2006-12-07 2009-08-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병
US8580789B2 (en) 2007-04-02 2013-11-12 The Cleveland Clinic Foundation Treating glaucoma
JP2013506005A (ja) * 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． 眼の繊維症の処置のための方法及び組成物
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
BRPI1002523B1 (pt) * 2010-07-14 2020-06-02 Universidade Federal De Minas Gerais Processo de síntese de complexos de cobre com atividade antitumoral
WO2014065863A1 (en) * 2012-10-22 2014-05-01 The Regents Of The University Of California Compositions and methods for promoting collagen-crosslinking
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
DE102014012675A1 (de) 2014-08-26 2016-03-03 Wavelight Gmbh Vernetzung von Augengewebe
ES2959242T3 (es) * 2016-03-08 2024-02-22 Univ Utah Res Found Agentes de reticulación y métodos asociados
US11524032B2 (en) * 2018-01-05 2022-12-13 University Of Utah Research Foundation Treatment of myopic progression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490389A (en) * 1976-03-11 1984-12-25 Nelson Research & Development Co. Contact lens preserving solution containing ascorbic acid or salts thereof
US7351715B2 (en) * 1998-09-21 2008-04-01 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2016162795A1 (en) * 2015-04-09 2016-10-13 Laboratori Baldacci S.P.A. Pyrrolidone carboxylic acid (pca) for ophthalmic use

Also Published As

Publication number Publication date
KR20250026890A (ko) 2025-02-25
US20210322470A1 (en) 2021-10-21
EP4324454A3 (en) 2024-05-01
EP3426262A4 (en) 2019-10-16
CA3016688A1 (en) 2017-09-14
AU2023202236B2 (en) 2025-05-29
EP4324454A2 (en) 2024-02-21
AU2023202236A1 (en) 2023-05-04
EP3426262C0 (en) 2023-08-23
US20260041714A1 (en) 2026-02-12
US11065275B2 (en) 2021-07-20
JP7900903B2 (ja) 2026-08-05
US20190083529A1 (en) 2019-03-21
AU2016396661A1 (en) 2018-09-27
EP3426262A1 (en) 2019-01-16
JP6929010B2 (ja) 2021-09-01
EP3426262B1 (en) 2023-08-23
JP2019511493A (ja) 2019-04-25
KR20180119654A (ko) 2018-11-02
WO2017155580A1 (en) 2017-09-14
KR102771170B1 (ko) 2025-02-24
ES2959242T3 (es) 2024-02-22
JP2021185154A (ja) 2021-12-09
JP2023153926A (ja) 2023-10-18

Similar Documents

Publication Publication Date Title
AU2023202236B2 (en) Cross-linking agents and associated methods
US12544400B2 (en) Treatment of myopic progression
AU2026201640A1 (en) Multi-agent ocular formulations and treatment methods
KR20230146550A (ko) 난시의 치료
HK40107891A (en) Cross-linking agents and associated methods
KR20240021734A (ko) 근시의 치료

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)